ASCO 2021 Percepta GSC
In this research, Dr. Sonali Sethi and colleagues assess the potential clinical utility of the Percepta Genomic Sequencing Classifier (GSC) in up-classifying pre-test high risk lung nodules to very high risk (>91%) after a nondiagnostic bronchoscopy.
Analytical Validation of the Percepta Genomic Sequencing Classifier; an RNA Next Generation Sequencing Assay for the Assessment of Lung Cancer Risk of Suspicious Pulmonary Nodules
Percepta GSC for risk stratification of suspicious lung nodules can be performed with high confidence in the clinical setting.
Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study
The down-classification of nodule malignancy risk with Percepta GSC decreased additional invasive procedures without a delay in time to diagnosis among those with lung cancer.
Improving Lung Cancer Risk Stratification Leveraging Whole Transcriptome RNA Sequencing and Machine Learning across Multiple Cohorts
The Percepta GSC demonstrated diagnostic accuracy in both down- and up-classification of cancer risk, providing physicians actionable information for many patients with inconclusive bronchoscopy.
Performance of the Percepta Genomic Sequencing Classifier (GSC) as a Complement to Bronchoscopy for Indeterminate Lung Nodules
Percepta GSC improves the diagnostic utility of bronchoscopy with a combined sensitivity of 96%. Hear Presentation.